Role of Neurohormonal Modulators in Heart Failure with Relatively Preserved Systolic Function

Cardiology Clinics

Volumn 26, Issue 1, 2008, Pages 23-40

  Rapp, Jonathan A ^a   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NEUROHORMONE; NITRIC ACID DERIVATIVE; PERINDOPRIL; PLACEBO; PROPRANOLOL; RAMIPRIL; SPIRONOLACTONE; TIMOLOL; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC HEART FAILURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERANCE; ECHOCARDIOGRAPHY; ECONOMIC ASPECT; EVIDENCE BASED PRACTICE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE COMPLIANCE; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; STATISTICAL ANALYSIS; SYSTOLE; SYSTOLIC HEART FAILURE; TACHYCARDIA; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG ADMINISTRATION SCHEDULE; HEART FAILURE; HUMANS; NEUROTRANSMITTER AGENTS; SYSTOLE;

EID: 39649121908     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.11.001     Document Type: Review

References (152)

1. American Heart Association. Heart disease and stroke statistics-2004 update (2003), American Heart Association, Dallas (TX)
2. American Heart Association. 2002 heart and stroke statistical update (2003), American Heart Association, Dallas (TX)
3. Miller L.W., and Missov E.D. Epidemiology of heart failure. Cardiol Clin 19 (2001) 547-555
4. Haldeman G.A., Croft J.B., Giles W.H., et al. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 137 (1999) 352-360
5. Hogg K., Swedlberg K., and McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43 (2004) 317-327
6. Cortina A., Reguero J., Segovia E., et al. Prevalence of heart failure in Asturias (a region in the north of Spain). Am J Cardiol 87 (2001) 1417-1419
7. Mosterd A., Hoes A.W., de Bruyne M.C., et al. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J 20 (1999) 447-455
8. Nielsen O.W., Hilden J., Larsen C.T., et al. Cross-sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk. Heart 86 (2001) 172-178
9. Hedberg P., Lonnberg I., Jonason T., et al. Left ventricular systolic dysfunction in 75-year-old men and women; a population-based study. Eur Heart J 22 (2001) 676-683
10. Morgan S., Smith H., Simpson I., et al. Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross-sectional survey. BMJ 318 (1999) 368-372
11. Kupari M., Lindroos M., Iivanainen A.M., et al. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med 241 (1997) 387-394
12. Ceia F., Fonseca C., Mota T., et al., EPICA Investigators. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 4 (2002) 531-539
13. Kitzman D.W., Gardin J.M., Gottdiener J.S., et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 87 (2001) 413-419
14. Devereux R.B., Roman M.J., Liu J.E., et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol 86 (2000) 1090-1096
15. Redfield M.M., Jacobsen S.J., Burnett Jr. J.C., et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289 (2003) 194-202
16. Vasan R.S., Benjamin E.J., and Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 26 (1995) 1565-1574
17. Smith G.L., Masoudi F.A., Vaccarino V., et al. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 41 (2003) 1510-1518
18. Fonarow GC for the ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 4 Suppl 7 (2003) S21-S30
19. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38 (2001) 2101-2113
20. McKee P.A., Castelli W.P., McNamara P.M., et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 285 (1971) 1441-1446
21. Piccini J.P., Klein L., Gheorghiade M., et al. New insights into diastolic heart failure: role of diabetes mellitus. Am J Med 116 5A (2004) 64S-75S
22. Maisel A.S., McCord J., Nowak R.M., et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing not Properly Multinational Study. J Am Coll Cardiol 41 (2003) 2018-2021
23. Zile M.R., and Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105 (2002) 1387-1393
24. Zile M.R., Catalin F.B., and Gaasch W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350 (2004) 1953-1959
25. Zile M.R. Heart failure with preserved ejection fraction: is this diastolic heart failure?. J Am Coll Cardiol 41 (2003) 1519-1522
26. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 19 (1998) 990-1003
27. Vasan R.S., and Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 101 (2000) 2118-2121
28. Gandhi S.K., Powers J.C., Nomeir A.M., et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 344 (2001) 17-22
29. Lenzen M.J., Scholte op Reimer W.J.M., Boersma E., et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 25 (2004) 1214-1220
30. Kitzman D.W., Little W.C., Brubaker P.H., et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288 (2002) 2144-2150
31. Chen H.H., Lainchbury J.G., Senni M., et al. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail 8 (2002) 279-287
32. McDermott M.M., Feinglass J., Sy J., et al. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. Am J Med 99 (1995) 629-635
33. Philbin E.F., Rocco T.A., Lindenmuth N.W., et al. Systolic versus diastolic heart failure in the community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 109 (2000) 605-613
34. Pernenkil R., Vinson J.M., Shah A.S., et al. Course and prognosis in patients > or = 70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am J Cardiol 79 (1997) 216-219
35. McDermott M.M., Feinglass J., Lee P.I., et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J 134 (1997) 728-736
36. Vasan R.S., Larson M.G., Benjamin E.J., et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33 (1999) 1948-1955
37. McAlister F.A., Teo K.K., Taher M., et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 138 (1999) 87-94
38. Senni M., Tribouilloy C.M., Rodeheffer R.J., et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 98 (1998) 2282-2289
39. Rich M.W., McSherry F., Williford W.O., et al. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG Study. J Am Coll Cardiol 38 (2001) 806-813
40. Tarantini L., Faggiano P., Senni M., et al. Clinical features and prognosis associated with a preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by cardiologists: data from the Italian Network on Congestive Heart Failure. Ital Heart J 3 (2002) 656-664
41. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997) 525-533
42. Judge K.W., Pawitan Y., Caldwell J., et al. Congestive heart failure symptoms in patients with preserved left ventricular systolic function: analysis of the CASS registry. J Am Coll Cardiol 18 (1991) 377-382
43. Bonow R.O., and Udelson J.E. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Intern Med 117 (1992) 502-510
44. McDonald I.G. The shape and movements of the human left ventricle during systole: a study by cineangiography and by cineradiography of epicardial markers. Am J Cardiol 26 (1970) 221-230
45. Ingels N.B., Daughters G.T., Stinson E.B., et al. Measurement of midwall myocardial dynamics in intact man by radiography of surgically implanted markers. Circulation 52 (1975) 859-867
46. Rothfeld J.M., LeWinter M.M., and Tischler M.D. Left ventricular systolic torsion and early diastolic filling by echocardiography in normal humans. Am J Cardiol 81 (1998) 1465-1469
47. Michelfelder E.C., Khoury P., Witt S.A., et al. Noncircumferential myofiber function: impact on early diastolic filling in children. J Am Soc Echocardiogr 14 (2001) 1065-1069
48. Rademakers F.E., Buchalter M.B., Rogers W.J., et al. Dissociation between left ventricular untwisting and filling: accentuation by catecholamines. Circulation 85 (1992) 1572-1581
49. Udelson J.E., Bacharach S.L., Cannon III R.O., et al. Minimum left ventricular pressure during beta-adrenergic stimulation in human subjects: evidence for elastic recoil and diastolic "suction" in the normal heart. Circulation 82 (1990) 1174-1182
50. Zile M.R., and Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure II. Causal mechanisms and treatment. Circulation 105 (2002) 1503-1508
51. Nayler W.G., Poole-Wilson P.A., and Williams A. Hypoxia and calcium. J Mol Cell Cardiol 11 (1979) 683-706
52. Henry P.D., Schuchleib R., Davis J., et al. Myocardial contracture and accumulation of mitochondrial calcium in ischemic rabbit heart. Am J Physiol 233 (1977) H677-H684
53. Weisfeldt M.L., Armstrong P., Scully H.E., et al. Incomplete relaxation between beats after myocardial hypoxia and ischemia. J Clin Invest 53 (1974) 1626-1636
54. Sordahl L.A., McCollum W.B., Wood W.G., et al. Mitochondria and sarcoplasmic reticulum function in cardiac hypertrophy and failure. Am J Physiol 224 (1973) 497-502
55. Ito Y., Suko J., and Chidsey C.A. Intracellular calcium and myocardial contractility. V. Calcium uptake of sarcoplasmic reticulum fractions in hypertrophied and failing rabbit hearts. J Mol Cell Cardiol 6 (1974) 237-247
56. Gwathmey J.K., Copelas L., MacKinnon R., et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 61 (1987) 70-76
57. Bell S.P., Nyland L., Tischler M.D., et al. Alterations in the determinants of diastolic suction during pacing tachycardia. Circ Res 87 (2000) 235-240
58. Cazorla O., Freiburg A., Helmes M., et al. Differential expression of cardiac titin isoforms and modulation of cellular stiffness. Circ Res 86 (2000) 59-67
59. Jalil J.E., Doering C.W., Janicki J.S., et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 64 (1989) 1041-1050
60. Weber K.T., Janicki J.S., Pick R., et al. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol 65 (1990) G1-G7
61. Kato S., Spinale F.G., Tanaka R., et al. Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am J Physiol 269 (1995) H863-H868
62. Raman V.K., Lee Y.A., and Lindpaintner K. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 76 (1995) 18D-23D
63. Dzau V.J. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 153 (1993) 937-942
64. Schunkert H., Dzau V.J., Tang S.S., et al. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility and relaxation. J Clin Invest 86 (1990) 1913-1920
65. Eberli F.R., Apstein C.S., Ngoy S., et al. Exacerbation of left ventricular ischemic diastolic dysfunction by pressure-overload hypertrophy: modification by specific inhibition of cardiac angiotensin converting enzyme. Circ Res 70 (1992) 931-943
66. Mochizuki T., Eberli F.R., Apstein C.S., et al. Exacerbation of ischemic dysfunction by angiotensin II in red cell-perfused rabbit hearts: Effects of coronary flow, contractility, and high-energy phosphate metabolism. J Clin Invest 89 (1992) 490-498
67. Zennaro M.C., Farman N., Bonbalet J.P., et al. Tissue-specific expression of alpha and beta messenger ribonucleic acid isoforms of the human mineralocorticoid receptor in normal and pathological states. J Clin Endocrinol Metab 82 (1997) 1345-1352
68. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 345 (2001) 1689-1697
69. Horisberger J.D., and Rossier B.C. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension 19 (1992) 221-227
70. Robert V., Van Thiem N., Cheav S.L., et al. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 24 (1994) 30-36
71. Khan N.U., and Movahed A. The role of aldosterone and aldosterone-receptor antagonists in heart failure. Rev Cardiovasc Med 5 (2004) 71-81
72. Laine G.A. Microvascular changes in the heart during chronic arterial hypertension. Circ Res 62 (1988) 953-960
73. White M., and Leenen F.H. Aging and cardiovascular responsiveness to beta-agonist in humans: role of changes in beta-receptor responses versus baroreflex activity. Clin Pharmacol Ther 56 (1994) 543-553
74. Lakatta E.G., and Yin F.C. Myocardial aging: functional alterations and related cellular mechanisms. Am J Physiol 242 (1982) H927-H941
75. O'Rourke M.F. Diastolic heart failure, diastolic left ventricular dysfunction and exercise intolerance. J Am Coll Cardiol 38 (2001) 803-805
76. Lamb H.J., Beyerbacht H.P., van der Laarse A., et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 99 (1999) 2261-2267
77. Zhang J., and McDonald K.M. Bioenergetic consequences of left ventricular remodeling. Circulation 92 (1995) 1011-1019
78. Yelamarty R.V., Moore R.L., Yu F.T., et al. Relaxation abnormalities in single cardiac myocytes from renovascular hypertensive rats. Am J Physiol 262 (1992) C980-C990
79. Leite-Moreira A.F., Correia-Pinto J., and Gillebert T.C. Afterload induced changes in myocardial relaxation: a mechanism for diastolic dysfunction. Cardiovasc Res 43 (1999) 344-353
80. Sadoshima J., Xu Y., Slayter H.S., et al. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75 (1993) 977-984
81. Van Heugten H.A., De Jonge H.W., Bezstarosti K., et al. Intracellular signaling and genetic reprogramming during agonist-induced hypertrophy of cardiomyocytes. Ann N Y Acad Sci 752 (1995) 343-352
82. Poulsen S.H., Jensen S.E., and Egstrup K. Longitudinal changes and prognostic implications of left ventricular diastolic function in first acute myocardial infarction. Am Heart J 137 (1999) 910-918
83. Pardaens K., Van Cleemput J., Vanhaecke J., et al. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart 78 (1997) 564-568
84. Gottdiener J.S., Arnold A.M., Aurigemma G.P., et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35 (2000) 1628-1637
85. Parker A.B., Yusuf S., and Naylor C.D. The relevance of subgroup-specific treatment effects: the Studies of Left Ventricular Dysfunction (SOLVD) revisited. Am Heart J 144 (2002) 941-947
86. Arnold J.M., Yusuf S., Young J., et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 107 (2003) 1284-1290
87. Seneviratne B.I. Diabetic cardiomyopathy: the preclinical phase. BMJ 1 (1977) 1444-1446
88. Raev D.C. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy?: an echocardiographic study of young type I diabetic patients. Diabetes Care 17 (1994) 633-639
89. Zabalgoitia M., Ismaeil M.F., Anderson L., et al. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 87 (2001) 320-323
90. Liu J.E., Palmieri V., Roman M.J., et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 37 (2001) 1943-1949
91. Uusitupa M., Siitonen O., Aro A., et al. Effect of correction of hyperglycemia on left ventricular function in non-insulin-dependent (type 2) diabetics. Acta Med Scand 213 (1983) 363-368
92. Hardin N. The myocardial and vascular pathology of diabetic cardiomyopathy. Coron Artery Dis 7 (1996) 99-108
93. Young M.E., McNulty P., and Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes. II. Potential mechanisms. Circulation 105 (2002) 1861-1870
94. Rupp H., Elimban V., and Dhalla N.S. Modification of myosin isozymes and SR Ca(2 +)-pump ATPase of the diabetic rat heart by lipid-lowering interventions. Mol Cell Biochem 132 (1994) 69-80
95. Bristow M.R. Why does the myocardium fail?: insights from basic science. Lancet 352 (1998) S8-S14
96. Depre C., Young M.E., Ying J., et al. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol 32 (2000) 985-996
97. Golfman L., Dixon I.M., Takeda N., et al. Differential changes in cardiac myofibrillar and sarcoplasmic reticular gene expression in alloxan-induced diabetes. Mol Cell Biochem 200 (1999) 15-25
98. Flarsheim C.E., Grupp I.L., and Matlib M.A. Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. Am J Physiol 271 (1996) H192-H202
99. Bristow M. Etomoxir: a new approach to treatment of chronic heart failure. Lancet 356 (2000) 1621-1622
100. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic HF and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003) 777-781
101. Officers ALLHAT and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
102. The Heart Outcomes Prevention Evaluation Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
103. Lonn E.M., Yusuf S., Jha P., et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90 (1994) 2056-2069
104. Schieffer B., Schieffer E., Hilfiker-Kleiner D., et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101 (2000) 1372-1378
105. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
106. Pedersen O.D., Bagger H., Kober L., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100 (1999) 376-380
107. Vermes E., Tardif J.C., Bourassa M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 10 (2003) 2926-2931
108. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
109. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-left ventricular hypertrophy study. Circulation 108 (2003) 1831-1838
110. Brilla C.G., Funck R.C., and Rupp H. Lisionpril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102 (2000) 1388-1393
111. Julius S., Kjeldsen S.E., Weber M., et al., VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
112. Dahlof B., Devereux R.B., Kjeldsen S.E., et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
113. Lithell H., Hansson L., Skoog I., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21 (2003) 875-886
114. Madrid A.H., Bueno M.G., Rebollo J.M., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106 (2002) 331-336
115. Devereux R.B., Gerdts E., Wachtell K., et al. Regression of hypertensive left ventricular hypertrophy by angiotensin receptor blockade versus beta-blockade: the LIFE trial (abstract). Am J Hypertens 15 (2002) 15A
116. Coope J., and Warrender T.S. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 293 (1986) 1145-1151
117. Ekbom T., Dahlof B., Hansson L., et al. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study. J Hypertens 10 (1992) 1525-1530
118. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 304 (1992) 405-412
119. Messerli F., and Grossman E. Beta-blockers in hypertension: is carvedilol different?. Am J Cardiol 93 Suppl (2004) 7B-12B
120. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304 (1981) 801-807
121. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA 247 (1982) 1707-1714
122. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: II. Morbidity results. JAMA 250 (1983) 2814-2819
123. Vantrimpont P., Rouleau J.L., Wun C.C., et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 29 (1997) 229-236
124. Spargias K.S., Hall A.S., Greenwood D.C., et al. Beta-blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. Heart 81 (1999) 25-32
125. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
126. Olshansky B., Rosenfeld L.E., Warner A.L., et al. The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study approaches to control rate in atrial fibrillation. J Am Coll Cardiol 43 (2004) 1201-1208
127. Kuhlkamp V., Schirdewan A., Stangl K., et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 36 (2000) 139-146
128. Schmieder R.E., Schlaich M.P., Klingbeil A.U., et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 13 (1998) 564-569
129. Palazzuoli A., Carrera A., Calabria P., et al. Effects of carvedilol therapy on restrictive diastolic filling pattern in chronic heart failure. Am Heart J 147 (2004) 1-7
130. Capomolla S., Febo O., Gnemmi M., et al. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 139 (2000) 596-608
131. Bergstrom A., Andersson B., Edner M., et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 6 (2004) 453-461
132. Taylor C.T. Eplerenone (Inspra) for hypertension. Am Fam Physician 69 (2004) 915-916
133. Williams G.H., Burgess E., Kolloch R.E., et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93 (2004) 990-996
134. White W.B., Duprez D., St. Hillaire R., et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41 (2003) 1021-1026
135. Flack J.M., Oparil S., Pratt J.H., et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 41 (2003) 1148-1155
136. Robert V., Heymes C., Silvestre J.S., et al. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt induced fibrosis. Hypertension 33 (1999) 981-986
137. Duprez D.A., DeBuyzere M.L., Rietzschel E.R., et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 19 (1998) 1371-1376
138. Bauersachs J., Heck M., Fraccarollo D., et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 39 (2002) 351-358
139. Brilla C.G., Matsubara L.S., and Weber K.T. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71 (1993) 12A-16A
140. Brilla C.G., Matsubara L.S., and Weber K.T. Anti-aldosterone treatment and prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25 (1993) 563-575
141. Lacolley P., Safar M.E., Lucet B., et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 37 (2001) 662-667
142. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 102 (2000) 2700-2706
143. Querejeta R., Varo N., Lopez B., et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 101 (2000) 1729-1735
144. Frierdich G., Schuh J., Brown M., et al. Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of aldosterone-induced hypertension and cardiac fibrosis. [abstract]. Am J Hypertens 11 (1998) 94
145. Suzuki G., Morita H., Mishima T., et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106 (2002) 2967-2972
146. Struthers A.D., and MacDonald T.M. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 61 (2004) 663-670
147. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
148. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
149. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
150. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
151. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357
152. Iribarren C., Karter A.J., Go A.S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 103 (2001) 2668-2673